NCT01898286View on ClinicalTrials.gov

Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277®

PHASE3TerminatedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

December 31, 2014

Conditions
Type 1 Diabetes
Interventions
DRUG

DiaPep277®

1 mg of DiaPep277® subcutaneously in the upper arm at 0, 3, 6, 9, 12, 15, 18, and 21 months, for a total of 8 administrations

Trial Locations (3)

28803

Mountain Diabetes and Endocrine Center, Asheville

30318

Atlanta Diabetes associates, Atlanta

48202

Henry Ford Medical Centers - New Center One, Detroit

Sponsors
All Listed Sponsors
lead

Andromeda Biotech Ltd.

INDUSTRY

NCT01898286 - Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277® | Biotech Hunter | Biotech Hunter